Abstract
Atopic dermatitis (AD) and food allergies are more prevalent and more severe in people with skin of color than White individuals. The American College of Allergy, Asthma, and Immunology (ACAAI) sought to understand the effects of racial disparities among patients with skin of color with AD and food allergies. The ACAAI surveyed its members (N = 200 completed), conducted interviews with health care providers and advocacy leaders, and hosted a roundtable to explore the challenges of diagnosis and management of AD and food allergies in people with skin of color and to discuss potential solutions. Most of the survey respondents (68%) agreed that racial disparities make it difficult for people with skin of color to receive adequate treatment for AD and food allergies. The interviews and roundtable identified access to care, burden of costs, policies and infrastructure that limit access to safe foods and patient education, and inadequate research involving people with skin of color as obstacles to care. Proposed solutions included identifying ways to recruit more people with skin of color into clinical trials and medical school, educating health care providers about diagnosis and treating AD and food allergy in people with skin of color, improving access to safe foods, creating and disseminating culturally appropriate materials for patients, and working toward longer appointment times for patients who need them. Challenges in AD and food allergy in persons with skin of color were identified by the ACAAI members. Solutions to these challenges were proposed to inspire actions to mitigate racial disparities in AD and food allergy.
Original language | English (US) |
---|---|
Pages (from-to) | 392-396.e2 |
Journal | Annals of Allergy, Asthma and Immunology |
Volume | 130 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2023 |
Funding
Medical writing and editorial assistance were provided by Erin P. Scott, PhD, of Scott Medical Communications, LLC, and were supported by the American College of Allergy, Asthma & Immunology. Disclosures: Dr Corbett has served as a consultant for ALK-Abelló and Takeda, an advisor for AstraZeneca, and a speaker for Optinose, Regeneron, and Sanofi. Ms Allen has served as a speaker for AstraZeneca. Dr Foggs has served as an advisor or consultant for Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Sanofi Aventis. Dr Fonacier has received institutional research and educational grants from Regeneron, Pfizer, and AstraZeneca and served as an advisor or consultant with Regeneron, AbbVie, Pfizer, and Lilly. Dr Gupta receives research support from the National Institutes of Health (NIH) (R21 ID # AI135705, R01 ID # AI130348, U01 ID # AI138907), Food Allergy Research & Education (FARE), Melchiorre Family Foundation, Sunshine Charitable Foundation, The Walder Foundation, UnitedHealth Group, Thermo Fisher Scientific, and Genentech; serves as a medical consultant/advisor for Genentech, Novartis, Aimmune LLC, Allergenis LLC, and FARE; and has ownership interest in Yobee Care, Inc. Dr Blaiss has served as a consultant or advisor for Sanofi, Regeneron, Lanier BioTherapeutics, Ready, Set, Food, and Merck. The remaining authors have no conflicts of interest to report. Funding: Funding for this research was provided by Novartis Pharmaceuticals, Inc.
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pulmonary and Respiratory Medicine